Journal profile · Medicine-Cardiology and Cardiovascular Medicine
Atherosclerosis: X
ISSN 2590-1354 · eISSN 1879-1484 · Elsevier
Atherosclerosis: X: subscription journal; APC about USD 2,100; review about 110 days (submission to acceptance, publisher); indexed in Scopus.
Scope
Aims, scope and focus
Cardiovascular disease (CVD) causes one third of all deaths worldwide and is a major threat to global health. Atherosclerosis aims to provide a comprehensive platform for researchers, clinicians and healthcare professionals to share the latest findings and advances in the field of atherosclerosis. Atherosclerosis covers a wide range of topics, including:Pathophysiology and Mechanisms: We explore the intricate cellular and molecular processes involved in atherogenesis, from the initial formation of fatty streaks to the development of complex plaques. We also welcome studies on cardiac biology and disease.Risk Factors: We consider manuscripts that examine both traditional and emerging risk factors for atherosclerosis, such as dyslipidaemia, hypertension, diabetes mellitus, thrombosis and genetic predisposition.Prevention of CVD: Since prevention will become a major focus in the future (see e.g. the European Cardiovascular Health Plan), an important focus will be on preventive strategies, including lifestyle modifications and pharmacological interventions.Diagnostics Techniques: We features articles on cutting-edge diagnostic techniques, ranging from invasive procedures such as selective coronary arteriography to non-invasive techniques such as blood biomarkers.Treatment Approaches: Atherosclerosis covers the latest developments in the treatment of atherosclerosis, including lipid-lowering therapies, anti-inflammatory treatments and novel targeted approaches aimed at modifying disease progression and improving clinical outcomes.Translational Research: We bridges the gap between basic science and clinical practice by highlighting translational studies that bring laboratory findings closer to practical applications in patient care.By fostering collaboration and knowledge exchange between researchers and clinicians, Atherosclerosis aims to accelerate progress in the understanding, prevention and treatment of atherosclerosis, ultimately improving the lives of the millions of people affected by this pervasive disease.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Cardiology and Cardiovascular Medicine
Editor-in-chief Jan BorénPublisher website
Editorial board by country: 2 in mainland China (about 1%); most named Netherlands 20, Germany 18, Italy 18, United States 16, Australia 15 (172 members with a country) Editorial board ↗Publisher website ·
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Not covered
Not covered by this edition.
CAS Xinrui Journal Ranking (March 2026)Not covered
Not covered by this edition.
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Cardiology and Cardiovascular Medicine | Q4 | 278/317 | 12th |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 0.3LetPub ·
- SJR 2026-06
- 0.17LetPub ·
- SNIP 2026-06
- 0.17LetPub ·
- h-index
- 0OpenAlex ·
- i10-index
- 0OpenAlex ·
- 2-year mean citedness
- 0OpenAlex ·
- Share of gold OA articles
- 0%LetPub ·
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Publisher-reported review time from the journal's website
110 dayssubmission to acceptance
The publisher's own definition applies; dates from this journal's articles in the last 24 months are not available yet, so the publisher's figure is used.
Figures by source
- Submission to first decision
- 7 daysPublisher website ·
- First decision after review
- 41 daysPublisher website ·
- Submission to acceptance
- 110 daysPublisher website ·
- Acceptance to publication
- 3 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Subscription journalLetPub
A subscription journal: articles are read by subscription or purchase, and authors usually pay no publication charge.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 2,100 | — | — | |
| Publisher website | USD 4,520 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access
- Open access Open Access
Article Publishing Charge (APC): USD 4,520 (excluding taxes). The amount you pay may be reduced during submission if applicable.Review this journal’s open access policy.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- ISSN
- 2590-1354
- Electronic ISSN
- 1879-1484
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Atherosclerosis: X
How long does peer review take at Atherosclerosis: X?
The publisher reports about 110 days (submission to acceptance). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Where are the editorial board members of Atherosclerosis: X based?
Of the 172 board members whose country the journal's board page names, 2 (about 1%) are in mainland China; the countries named most often are Netherlands (20), Germany (18) and Italy (18). Counted from the institutions listed on the board page; for reference only.
Which databases index Atherosclerosis: X?
According to LetPub and DOAJ records, Atherosclerosis: X is indexed in Scopus.
Is Atherosclerosis: X open access, and what is the APC?
Atherosclerosis: X is a subscription journal. APC about USD 2,100.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .